© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 13, 1113-1124,
July 7, 1999
© 1999 Oxford University Press
REVIEW |
Detection and Clinical Importance of Micrometastatic Disease
Affiliations of authors: K. Pantel, Universitätsfrauenklinik, Universitätsklinikum Eppendorf, Hamburg, Germany; R. J. Cote, Department of Pathology and Urology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles; Ø. Fodstad, Department of Tumour Biology, The Norwegian Radium Hospital, Montebello, Oslo, Norway.
Correspondence to: Klaus Pantel, M.D., Ph.D., Universitätsfrauenklinik, Universitätsklinikum Eppendorf, Martinistr. 52, D-0246 Hamburg, Germany (e-mail: antel{at}UKE.uni-hamburg.de).
Metastatic relapse in patients with solid tumors is caused by systemic preoperative or perioperative dissemination of tumor cells. The presence of individual tumor cells in bone marrow and in peripheral blood can be detected by immunologic or molecular methods and is being regarded increasingly as a clinically relevant prognostic factor. Because the goal of adjuvant therapy is the eradication of occult micrometastatic tumor cells before metastatic disease becomes clinically evident, the early detection of micrometastases could identify the patients who are most (and least) likely to benefit from adjuvant therapy. In addition, more sensitive methods for detecting such cells should increase knowledge about the biologic mechanisms of metastasis and improve the diagnosis and treatment of micrometastatic disease. In contrast to solid metastatic tumors, micrometastatic tumor cells are appropriate targets for intravenously applied agents because macromolecules and immunocompetent effector cells should have access to the tumor cells. Because the majority of micrometastatic tumor cells may be nonproliferative (G0 phase), standard cytotoxic chemotherapies aimed at proliferating cells may be less effective, which might explain, in part, the failure of chemotherapy. Thus, adjuvant therapies that are aimed at dividing and quiescent cells, such as antibody-based therapies, are of considerable interest. From a literature search that used the databases MEDLINE®, CANCERLIT®, Biosis®, Embase®, and SciSearch®, we discuss the current state of research on minimal residual cancer in patients with epithelial tumors and the diagnostic and clinical implications of these findings.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Xenidis, M. Ignatiadis, S. Apostolaki, M. Perraki, K. Kalbakis, S. Agelaki, E. N. Stathopoulos, G. Chlouverakis, E. Lianidou, S. Kakolyris, et al. Cytokeratin-19 mRNA-Positive Circulating Tumor Cells After Adjuvant Chemotherapy in Patients With Early Breast Cancer J. Clin. Oncol., May 1, 2009; 27(13): 2177 - 2184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Weckermann, B. Polzer, T. Ragg, A. Blana, G. Schlimok, H. Arnholdt, S. Bertz, R. Harzmann, and C. A. Klein Perioperative Activation of Disseminated Tumor Cells in Bone Marrow of Patients With Prostate Cancer J. Clin. Oncol., April 1, 2009; 27(10): 1549 - 1556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kitago, K. Koyanagi, T. Nakamura, Y. Goto, M. Faries, S. J. O'Day, D. L. Morton, S. Ferrone, and D. S.B. Hoon mRNA Expression and BRAF Mutation in Circulating Melanoma Cells Isolated from Peripheral Blood with High Molecular Weight Melanoma-Associated Antigen-Specific Monoclonal Antibody Beads Clin. Chem., April 1, 2009; 55(4): 757 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Alix-Panabieres, S. Riethdorf, and K. Pantel Circulating Tumor Cells and Bone Marrow Micrometastasis Clin. Cancer Res., August 15, 2008; 14(16): 5013 - 5021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Diomedi-Camassei, H. P. McDowell, M. A. De Ioris, S. Uccini, P. Altavista, G. Raschella, R. Vitali, O. Mannarino, L. De Sio, D. A. Cozzi, et al. Clinical Significance of CXC Chemokine Receptor-4 and c-Met in Childhood Rhabdomyosarcoma Clin. Cancer Res., July 1, 2008; 14(13): 4119 - 4127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Apostolaki, M Perraki, A Pallis, V Bozionelou, S Agelaki, P Kanellou, A Kotsakis, E Politaki, K Kalbakis, A Kalykaki, et al. Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance Ann. Onc., May 1, 2007; 18(5): 851 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lacroix Significance, detection and markers of disseminated breast cancer cells Endocr. Relat. Cancer, December 1, 2006; 13(4): 1033 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Xenidis, M. Perraki, M. Kafousi, S. Apostolaki, I. Bolonaki, A. Stathopoulou, K. Kalbakis, N. Androulakis, C. Kouroussis, T. Pallis, et al. Predictive and Prognostic Value of Peripheral Blood Cytokeratin-19 mRNA-Positive Cells Detected by Real-Time Polymerase Chain Reaction in Node-Negative Breast Cancer Patients J. Clin. Oncol., August 10, 2006; 24(23): 3756 - 3762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Schulz, T. Hyslop, J. Haaf, C. Bonaccorso, K. Nielsen, M. E. Witek, R. Birbe, J. Palazzo, D. Weinberg, and S. A. Waldman A Validated Quantitative Assay to Detect Occult Micrometastases by Reverse Transcriptase-Polymerase Chain Reaction of Guanylyl Cyclase C in Patients with Colorectal Cancer Clin. Cancer Res., August 1, 2006; 12(15): 4545 - 4552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Mescoli, M Rugge, S Pucciarelli, V M Russo, G Pennelli, M Guido, and D Nitti High prevalence of isolated tumour cells in regional lymph nodes from pN0 colorectal cancer J. Clin. Pathol., August 1, 2006; 59(8): 870 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Pagliarulo, D. Hawes, F. H. Brands, S. Groshen, J. Cai, J. P. Stein, G. Lieskovsky, D. G. Skinner, and R. J. Cote Detection of Occult Lymph Node Metastases in Locally Advanced Node-Negative Prostate Cancer J. Clin. Oncol., June 20, 2006; 24(18): 2735 - 2742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Scoggins, M. I. Ross, D. S. Reintgen, R. D. Noyes, J. S. Goydos, P. D. Beitsch, M. M. Urist, S. Ariyan, B. S. Davidson, J. J. Sussman, et al. Prospective Multi-Institutional Study of Reverse Transcriptase Polymerase Chain Reaction for Molecular Staging of Melanoma J. Clin. Oncol., June 20, 2006; 24(18): 2849 - 2857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Koyanagi, T. Mori, S. J. O'Day, S. R. Martinez, H.-J. Wang, and D. S.B. Hoon Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res., June 15, 2006; 66(12): 6111 - 6117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Wulfing, J. Borchard, H. Buerger, S. Heidl, K. S. Zanker, L. Kiesel, and B. Brandt HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients. Clin. Cancer Res., March 15, 2006; 12(6): 1715 - 1720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Koyanagi, S. J. O'Day, R. Gonzalez, K. Lewis, W. A. Robinson, T. T. Amatruda, C. Kuo, H.-J. Wang, R. Milford, D. L. Morton, et al. Microphthalmia Transcription Factor as a Molecular Marker for Circulating Tumor Cell Detection in Blood of Melanoma Patients Clin. Cancer Res., February 15, 2006; 12(4): 1137 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Kaifi, E. F. Yekebas, P. Schurr, D. Obonyo, R. Wachowiak, P. Busch, A. Heinecke, K. Pantel, and J. R. Izbicki Tumor-Cell Homing to Lymph Nodes and Bone Marrow and CXCR4 Expression in Esophageal Cancer J Natl Cancer Inst, December 21, 2005; 97(24): 1840 - 1847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Delord, C. Allal, M. Canal, E. Mery, P. Rochaix, I. Hennebelle, A. Pradines, E. Chatelut, R. Bugat, S. Guichard, et al. Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma Ann. Onc., December 1, 2005; 16(12): 1889 - 1897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Willipinski-Stapelfeldt, S. Riethdorf, V. Assmann, U. Woelfle, T. Rau, G. Sauter, J. Heukeshoven, and K. Pantel Changes in Cytoskeletal Protein Composition Indicative of an Epithelial-Mesenchymal Transition in Human Micrometastatic and Primary Breast Carcinoma Cells Clin. Cancer Res., November 15, 2005; 11(22): 8006 - 8014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Koyanagi, S. J. O'Day, R. Gonzalez, K. Lewis, W. A. Robinson, T. T. Amatruda, H.-J. Wang, R. M. Elashoff, H. Takeuchi, N. Umetani, et al. Serial Monitoring of Circulating Melanoma Cells During Neoadjuvant Biochemotherapy for Stage III Melanoma: Outcome Prediction in a Multicenter Trial J. Clin. Oncol., November 1, 2005; 23(31): 8057 - 8064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J.M. Braakhuis, R. H. Brakenhoff, and C. R. Leemans Second Field Tumors: A New Opportunity for Cancer Prevention? Oncologist, August 1, 2005; 10(7): 493 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. S. Bruland, H. Hoifodt, G. Saeter, S. Smeland, and O. Fodstad Hematogenous Micrometastases in Osteosarcoma Patients Clin. Cancer Res., July 1, 2005; 11(13): 4666 - 4673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Koyanagi, C. Kuo, T. Nakagawa, T. Mori, H. Ueno, A. R. Lorico Jr, H.-J. Wang, E. Hseuh, S. J. O'Day, and D. S.B. Hoon Multimarker Quantitative Real-Time PCR Detection of Circulating Melanoma Cells in Peripheral Blood: Relation to Disease Stage in Melanoma Patients Clin. Chem., June 1, 2005; 51(6): 981 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Reinholz, A. Nibbe, L. M. Jonart, K. Kitzmann, V. J. Suman, J. N. Ingle, R. Houghton, B. Zehentner, P. C. Roche, and W. L. Lingle Evaluation of a Panel of Tumor Markers for Molecular Detection of Circulating Cancer Cells in Women with Suspected Breast Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3722 - 3732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hockel and N. Dornhofer The Hydra Phenomenon of Cancer: Why Tumors Recur Locally after Microscopically Complete Resection Cancer Res., April 15, 2005; 65(8): 2997 - 3002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. N. Stathopoulos, E. Sanidas, M. Kafousi, D. Mavroudis, J. Askoxylakis, V. Bozionelou, M. Perraki, D. Tsiftsis, and V. Georgoulias Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes Ann. Onc., February 1, 2005; 16(2): 240 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V Choesmel, F Foucault, J P Thiery, and N Blin Design of a real time quantitative PCR assay to assess global mRNA amplification of small size specimens for microarray hybridisation J. Clin. Pathol., December 1, 2004; 57(12): 1278 - 1287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Colnot, E. J. C. Nieuwenhuis, D. J. Kuik, C. R. Leemans, J. Dijkstra, G. B. Snow, G. A. M. S. van Dongen, and R. H. Brakenhoff Clinical Significance of Micrometastatic Cells Detected by E48 (Ly-6D) Reverse Transcription-Polymerase Chain Reaction in Bone Marrow of Head and Neck Cancer Patients Clin. Cancer Res., December 1, 2004; 10(23): 7827 - 7833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A M Gilbey, D Burnett, R E Coleman, and I Holen The detection of circulating breast cancer cells in blood J. Clin. Pathol., September 1, 2004; 57(9): 903 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Lange and D. W. Lin Does the Who and How of Surgery in Bladder Cancer Matter? J. Clin. Oncol., July 15, 2004; 22(14): 2762 - 2764. [Full Text] [PDF]
|
|
|
|
|
|
M. P. Tabor, R. H. Brakenhoff, H. J. Ruijter-Schippers, J. A. Kummer, C. R. Leemans, and B. J. M. Braakhuis Genetically Altered Fields as Origin of Locally Recurrent Head and Neck Cancer: A Retrospective Study Clin. Cancer Res., June 1, 2004; 10(11): 3607 - 3613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gangnus, S. Langer, E. Breit, K. Pantel, and M. R. Speicher Genomic Profiling of Viable and Proliferative Micrometastatic Cells from Early-Stage Breast Cancer Patients Clin. Cancer Res., May 15, 2004; 10(10): 3457 - 3464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Hoang, J. D'Cunha, S. H. Tawfic, A. C. Gruessner, R. A. Kratzke, and M. A. Maddaus Expression profiling of non-small cell lung carcinoma identifies metastatic genotypes based on lymph node tumor burden J. Thorac. Cardiovasc. Surg., May 1, 2004; 127(5): 1332 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Naume, G. Wiedswang, E. Borgen, G. Kvalheim, R. Karesen, H. Qvist, J. Janbu, T. Harbitz, and J. M. Nesland The Prognostic Value of Isolated Tumor Cells in Bone Marrow in Breast Cancer Patients: Evaluation of Morphological Categories and the Number of Clinically Significant Cells Clin. Cancer Res., May 1, 2004; 10(9): 3091 - 3097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Woelfle, G. Sauter, S. Santjer, R. Brakenhoff, and K. Pantel Down-Regulated Expression of Cytokeratin 18 Promotes Progression of Human Breast Cancer Clin. Cancer Res., April 15, 2004; 10(8): 2670 - 2674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-Y. Pierga, C. Bonneton, A. Vincent-Salomon, P. de Cremoux, C. Nos, N. Blin, P. Pouillart, J.-P. Thiery, and H. Magdelenat Clinical Significance of Immunocytochemical Detection of Tumor Cells Using Digital Microscopy in Peripheral Blood and Bone Marrow of Breast Cancer Patients Clin. Cancer Res., February 15, 2004; 10(4): 1392 - 1400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Pantel, V. Muller, M. Auer, N. Nusser, N. Harbeck, and S. Braun Detection and Clinical Implications of Early Systemic Tumor Cell Dissemination in Breast Cancer Clin. Cancer Res., December 15, 2003; 9(17): 6326 - 6334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mitas, L. Hoover, G. Silvestri, C. Reed, M. Green, A. T. Turrisi, C. Sherman, K. Mikhitarian, D. J. Cole, M. I. Block, et al. Lunx Is a Superior Molecular Marker for Detection of Non-Small Lung Cell Cancer in Peripheral Blood J. Mol. Diagn., November 1, 2003; 5(4): 237 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Partridge, R. Brakenhoff, E. Phillips, K. Ali, R. Francis, R. Hooper, K. Lavery, A. Brown, and J. Langdon Detection of Rare Disseminated Tumor Cells Identifies Head and Neck Cancer Patients at Risk of Treatment Failure Clin. Cancer Res., November 1, 2003; 9(14): 5287 - 5294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Woelfle, J. Cloos, G. Sauter, L. Riethdorf, F. Janicke, P. van Diest, R. Brakenhoff, and K. Pantel Molecular Signature Associated with Bone Marrow Micrometastasis in Human Breast Cancer Cancer Res., September 15, 2003; 63(18): 5679 - 5684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Wiedswang, E. Borgen, R. Karesen, G. Kvalheim, J.M. Nesland, H. Qvist, E. Schlichting, T. Sauer, J. Janbu, T. Harbitz, et al. Detection of Isolated Tumor Cells in Bone Marrow Is an Independent Prognostic Factor in Breast Cancer J. Clin. Oncol., September 15, 2003; 21(18): 3469 - 3478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Cote Occult metastases: real harm or false alarm? J. Thorac. Cardiovasc. Surg., August 1, 2003; 126(2): 332 - 333. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Marchevsky, J.-H. Qiao, S. Krajisnik, J. M. Mirocha, and R. J. McKenna The prognostic significance of intranodal isolated tumor cells and micrometastases in patients with non-small cell carcinoma of the lung J. Thorac. Cardiovasc. Surg., August 1, 2003; 126(2): 551 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Schmidt-Kittler, T. Ragg, A. Daskalakis, M. Granzow, A. Ahr, T. J. F. Blankenstein, M. Kaufmann, J. Diebold, H. Arnholdt, P. Muller, et al. From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression PNAS, June 24, 2003; 100(13): 7737 - 7742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Xenidis, I. Vlachonikolis, D. Mavroudis, M. Perraki, A. Stathopoulou, N. Malamos, C. Kouroussis, S. Kakolyris, S. Apostolaki, N. Vardakis, et al. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer Ann. Onc., June 1, 2003; 14(6): 849 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hegewisch-Becker, K. Braun, M. Otte, A. Corovic, D. Atanackovic, A. Nierhaus, D. K. Hossfeld, and K. Pantel Effects of Whole Body Hyperthermia (41.8{degrees}C) on the Frequency of Tumor Cells in the Peripheral Blood of Patients with Advanced Malignancies Clin. Cancer Res., June 1, 2003; 9(6): 2079 - 2084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kakiuchi, Y. Daigo, T. Tsunoda, S. Yano, S. Sone, and Y. Nakamura Genome-Wide Analysis of Organ-Preferential Metastasis of Human Small Cell Lung Cancer in Mice Mol. Cancer Res., May 1, 2003; 1(7): 485 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-S. Jung, K.-J. Lee, H.-J. Kim, H. E. Yim, J. S. Park, E.-Y. Soh, M.-W. Kim, and H. B. Park Clinical Significance of Bone Marrow Micrometastasis Detected by Nested RT-PCR for Keratin-19 in Breast Cancer Patients Jpn. J. Clin. Oncol., April 1, 2003; 33(4): 167 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Wascher, K. T. Huynh, A. E. Giuliano, N. M. Hansen, F. R. Singer, D. Elashoff, and D. S. B. Hoon Stanniocalcin-1: A Novel Molecular Blood and Bone Marrow Marker for Human Breast Cancer Clin. Cancer Res., April 1, 2003; 9(4): 1427 - 1435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Schleiermacher, M. Peter, O. Oberlin, T. Philip, H. Rubie, F. Mechinaud, D. Sommelet-Olive, J. Landman-Parker, D. Bours, J. Michon, et al. Increased Risk of Systemic Relapses Associated With Bone Marrow Micrometastasis and Circulating Tumor Cells in Localized Ewing Tumor J. Clin. Oncol., January 1, 2003; 21(1): 85 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Stathopoulou, I. Vlachonikolis, D. Mavroudis, M. Perraki, Ch. Kouroussis, S. Apostolaki, N. Malamos, S. Kakolyris, A. Kotsakis, N. Xenidis, et al. Molecular Detection of Cytokeratin-19-Positive Cells in the Peripheral Blood of Patients With Operable Breast Cancer: Evaluation of Their Prognostic Significance J. Clin. Oncol., August 15, 2002; 20(16): 3404 - 3412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F A Vlems, J H S Diepstra, I M H A Cornelissen, T J M Ruers, M J L Ligtenberg, C J A Punt, J H J M van Krieken, T. Wobbes, and G N P van Muijen Limitations of cytokeratin 20 RT-PCR to detect disseminated tumour cells in blood and bone marrow of patients with colorectal cancer: expression in controls and downregulation in tumour tissue Mol. Pathol., June 1, 2002; 55(3): 156 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Passlick, B. Kubuschock, W. Sienel, O. Thetter, K. Pantel, and J.R. Izbicki Mediastinal lymphadenectomy in non-small cell lung cancer: effectiveness in patients with or without nodal micrometastases -- results of a preliminary study Eur. J. Cardiothorac. Surg., March 1, 2002; 21(3): 520 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Silva, M. J. Tome, A. E. Correia, and J. L. Passos-Coelho Human mammaglobin RT-PCR assay for detection of occult breast cancer cells in hematopoietic products Ann. Onc., March 1, 2002; 13(3): 422 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Solakoglu, C. Maierhofer, G. Lahr, E. Breit, P. Scheunemann, I. Heumos, U. Pichlmeier, G. Schlimok, R. Oberneder, M. W. Kollermann, et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors PNAS, February 19, 2002; 99(4): 2246 - 2251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Flatmark, K. Bjornland, H. O. Johannessen, E. Hegstad, R. Rosales, L. Harklau, J. H. Solhaug, R. S. Faye, O. Soreide, and O. Fodstad Immunomagnetic Detection of Micrometastatic Cells in Bone Marrow of Colorectal Cancer Patients Clin. Cancer Res., February 1, 2002; 8(2): 444 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kufer, A. Zippelius, R. Lutterbuse, I. Mecklenburg, T. Enzmann, A. Montag, D. Weckermann, B. Passlick, N. Prang, P. Reichardt, et al. Heterogeneous Expression of MAGE-A Genes in Occult Disseminated Tumor Cells: A Novel Multimarker Reverse Transcription-Polymerase Chain Reaction for Diagnosis of Micrometastatic Disease Cancer Res., January 1, 2002; 62(1): 251 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.-F. Solomayer, I. J. Diel, G. Salanti, M. Hahn, C. Gollan, F. Schutz, and G. Bastert Time Independence of the Prognostic Impact of Tumor Cell Detection in the Bone Marrow of Primary Breast Cancer Patients Clin. Cancer Res., December 1, 2001; 7(12): 4102 - 4108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kasimir-Bauer, S. Mayer, P. Bojko, D. Borquez, R. Neumann, and S. Seeber Survival of Tumor Cells in Stem Cell Preparations and Bone Marrow of Patients with High-Risk or Metastatic Breast Cancer after Receiving Dose-intensive or High-Dose Chemotherapy Clin. Cancer Res., June 1, 2001; 7(6): 1582 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Wu, A. Mazumder, R. L. Martuza, X. Liu, M. Thein, K. R. Meehan, and S. D. Rabkin Biological Purging of Breast Cancer Cells Using an Attenuated Replication-competent Herpes Simplex Virus in Human Hematopoietic Stem Cell Transplantation Cancer Res., April 1, 2001; 61(7): 3009 - 3015. [Abstract] [Full Text]
|
|
|
|
|
|
S. Braun, B. S. Cevatli, C. Assemi, W. Janni, C. R.M. Kentenich, C. Schindlbeck, D. Rjosk, and F. Hepp Comparative Analysis of Micrometastasis to the Bone Marrow and Lymph Nodes of Node-Negative Breast Cancer Patients Receiving No Adjuvant Therapy J. Clin. Oncol., March 1, 2001; 19(5): 1468 - 1475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Takahashi, R. Kawanishi-Tabata, A. Haba, M. Tabata, Y. Haruta, H. Tsai, and B. K. Seon Association of Serum Endoglin with Metastasis in Patients with Colorectal, Breast, and Other Solid Tumors, and SuppressiveEffect of Chemotherapy on the Serum Endoglin Clin. Cancer Res., March 1, 2001; 7(3): 524 - 532. [Abstract] [Full Text]
|
|
|
|
|
|
B. Gerber, A. Krause, H. Muller, D. Richter, T. Reimer, J. Makovitzky, C. Herrnring, U. Jeschke, G. Kundt, and K. Friese Simultaneous Immunohistochemical Detection of Tumor Cells in Lymph Nodes and Bone Marrow Aspirates in Breast Cancer and Its Correlation With Other Prognostic Factors J. Clin. Oncol., February 15, 2001; 19(4): 960 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hosch, J. Kraus, P. Scheunemann, J. R. Izbicki, C. Schneider, U. Schumacher, K. Witter, M. R. Speicher, and K. Pantel Malignant Potential and Cytogenetic Characteristics of Occult Disseminated Tumor Cells in Esophageal Cancer Cancer Res., December 1, 2000; 60(24): 6836 - 6840. [Abstract] [Full Text]
|
|
|
|
|
|
K. D. Bauer, Jose de la Torre-Bueno, I. J. Diel, D. Hawes, W. J. Decker, C. Priddy, B. Bossy, S. Ludmann, K. Yamamoto, A. S. Masih, et al. Reliable and Sensitive Analysis of Occult Bone Marrow Metastases Using Automated Cellular Imaging Clin. Cancer Res., September 1, 2000; 6(9): 3552 - 3559. [Abstract] [Full Text]
|
|
|
|
|
|
A. Zippelius, R. Lutterbüse, G. Riethmüller, and K. Pantel Analytical Variables of Reverse Transcription-Polymerase Chain Reaction-based Detection of Disseminated Prostate Cancer Cells Clin. Cancer Res., July 1, 2000; 6(7): 2741 - 2750. [Abstract] [Full Text]
|
|
|
|
|
|
D. S. B. Hoon, P. Bostick, C. Kuo, T. Okamoto, H.-J. Wang, R. Elashoff, and D. L. Morton Molecular Markers in Blood as Surrogate Prognostic Indicators of Melanoma Recurrence Cancer Res., April 1, 2000; 60(8): 2253 - 2257. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Braun, K. Pantel, P. Muller, W. Janni, F. Hepp, C. R.M. Kentenich, S. Gastroph, A. Wischnik, T. Dimpfl, G. Kindermann, et al. Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II, or III Breast Cancer N. Engl. J. Med., February 24, 2000; 342(8): 525 - 533. [Abstract] [Full Text] [PDF]
|
|